UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
[X]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For
the quarterly period ended December 31, 2020
or
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
000-56090
Commission File Number
PHARMAGREEN
BIOTECH INC.
(Exact
name of registrant as specified in its charter)
Nevada 98-0491567
(State
or other jurisdiction of incorporation or
organization) (I.R.S. Employer Identification No.)
2987 Blackbear Court, Coquitlam, British
Columbia V3E
3A2
(Address
of principal executive offices)(Zip Code)
702-803-9404
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.
(X)Yes
(_) No
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).
(_)Yes
(_) No
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or a smaller reporting company. See the definitions of “large
accelerated filer,” “accelerated filer” and “smaller reporting
company” in Rule 12b-2 of the Exchange Act:
Large
accelerated filer
|
¨
|
Non-accelerated filer
|
¨
|
Accelerated filer
|
¨
|
Smaller reporting company
|
x
|
|
|
Emerging Growth
|
x
|
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act (X)
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
(
) Yes (X) No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or
15(d) of the Securities Exchange Act of 1934 subsequent to the
distribution of securities under a plan confirmed by a court.
(
) Yes ( ) No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer’s
classes of common stock, as of the latest practicable date. As of
February 19, 2021, we had 314,261,669 shares of common stock issued
and outstanding.
Explanatory
Note: The purpose of this Amendment No. 1 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended December 31,
2020, filed with the Securities and Exchange Commission on February
22, 2021 (the “Form 10-Q”), is to include financial statements in
XBRL format.
This
Amendment No. 1 to the Form 10-Q speaks as of the original filing
date of the Form 10-Q, does not reflect events that may have
occurred subsequent to the original filing date and does not modify
or update the disclosures made in the original Form 10-Q except as
noted above.
Item 6. Exhibits.
The following
documents are filed as a part of this report or are incorporated by
reference to previous filings, if so indicated:
Exhibit
Number
|
|
Description
|
|
|
|
|
|
|
31.1
(1)
|
|
Certification of
Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
of the Securities Exchange Act of 1934*
|
|
|
|
31.2
(1)
|
|
Certification of
Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of
the Securities Exchange Act of 1934**
|
|
|
|
32.1
(1)
|
|
Certification of
Chief Executive Officer under Section 1350 as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.2
(1)
|
|
Certification of
Principal Financial Officer under Section 1350 as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002**
|
|
|
|
101.INS
(2)
|
|
XBRL Instance
File
|
|
|
|
101.SCH
(2)
|
|
XBRL Taxonomy Schema
Linkbase Document
|
|
|
|
101.CAL
(2)
|
|
XBRL Taxonomy
Extension Calculation Linkbase Document
|
|
|
|
101.DEF
(2)
|
|
XBRL Taxonomy
Extension Definition Linkbase Document
|
|
|
|
101.LAB
(2)
|
|
XBRL Taxonomy
Extension Label Linkbase Document
|
|
|
|
101.PRE
(2)
|
|
XBRL Taxonomy
Extension Presentation Linkbase Document
|
(1)These
exhibits were previously filed in the registrant’s Form 10-Q for
the quarterly period ended December 31, 2020, filed with the
Securities and Exchange Commission on December 31, 2020.
(2)Filed
herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
Pharmagreen
Biotech Inc.
|
|
|
|
By:
|
/s/ Peter Wojcik
|
|
|
Peter Wojcik
|
|
|
President and
Director
Principal Executive
Officer
|
|
|
|
By:
|
/s/ Terry Kwan
|
|
|
Terry Kwan
|
|
|
Principal Accounting
Officer
|
Dated February 23,
2021